<PAGE> 1
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D. C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report: January 4, 2001
Date of earliest event reported: December 28, 2000
AVIRON
(Exact name of registrant as specified in its charter)
DELAWARE
(State or other jurisdiction of incorporation)
<TABLE>
<S> <C>
0-20815 77-0309686
(Commission File No.) (IRS Employer Identification No.)
</TABLE>
297 N. BERNARDO AVENUE
MOUNTAIN VIEW CALIFORNIA 94043
(Address of principal executive offices and zip code)
Registrant's telephone number, including area code: (650) 919-6500
<PAGE> 2
ITEM 5. OTHER EVENTS.
On December 28, 2000, the U.S. Food and Drug Administration accepted for
filing Aviron's Biologics License Application for its investigational intranasal
influenza vaccine, FluMist(TM). On December 29, 2000, Aviron announced the
acceptance for filing in a press release, a copy of which is attached as an
exhibit to this Form 8-K and is incorporated by reference in its entirety.
ITEM 7. EXHIBITS.
Exhibit 99.1 Press Release, dated December 29, 2000, entitled "FDA accepts
FluMist(TM) Biologics License Application (BLA) for review ---
Triggers $15.5 million payment from American Home Products."
2
<PAGE> 3
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned, hereunto duly authorized.
AVIRON
Dated: January 4, 2001 By: /s/ C. Boyd Clarke
-------------------------------------
C. Boyd Clarke
President and Chief Executive Officer
3
<PAGE> 4
INDEX TO EXHIBITS
<TABLE>
<S> <C>
Exhibit 99.1 Press Release, dated December 29, 2000, entitled "FDA accepts
FluMist(TM) Biologics License Application (BLA) for review ---
Triggers $15.5 million payment from American Home Products."
</TABLE>
4
